Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)
| Market Cap | 11.94B +3.7% |
| Revenue (ttm) | 3.06B +9.9% |
| Net Income | 543.81M +12.8% |
| EPS | 2.60 +12.8% |
| Shares Out | n/a |
| PE Ratio | 21.95 |
| Forward PE | 14.64 |
| Dividend | 1.47 (2.63%) |
| Ex-Dividend Date | Nov 24, 2025 |
| Volume | n/a |
| Average Volume | 401 |
| Open | 55.88 |
| Previous Close | 55.88 |
| Day's Range | 55.88 - 55.88 |
| 52-Week Range | 55.88 - 65.44 |
| Beta | 0.52 |
| RSI | 55.15 |
| Earnings Date | May 12, 2026 |
About RCDTF
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing’s syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acety... [Read more]
Financial Performance
In 2025, RCDTF's revenue was 2.62 billion, an increase of 11.82% compared to the previous year's 2.34 billion. Earnings were 443.62 million, an increase of 6.51%.
Financial numbers in EUR Financial StatementsNews
Recordati Q1 Net Income Rises; Confirms 2026 Financial Targets
(RTTNews) - Recordati (REC.MI) reported that its first quarter net income grew 22.4% to 153.06 million euros from 125.04 million euros, prior year. Earnings per share rose to 0.732 euros from 0.598 eu...
What To Expect From Recordati SpA (MIL:REC) Q1 2026 Earnings
What To Expect From Recordati SpA (MIL:REC) Q1 2026 Earnings
Recordati SpA (MIL:REC) Q1 2026 Earnings Report Preview: What To Look For
Recordati SpA (MIL:REC) Q1 2026 Earnings Report Preview: What To Look For
Recordati Industria Chimica e Farmaceutica Earnings Call Transcript: Q4 2025
Revenue grew 11.8% to €2.62B in 2025, with rare disease up 29.7% and EBITDA margin at 37.8%. 2026 guidance targets €2.73–2.8B revenue and high-teens rare disease growth, despite FX headwinds. Investments in ISTURISA and new partnerships, including Moderna, support future growth.
Recordati Industria Chimica e Farmaceutica Transcript: 44th Annual J.P. Morgan Healthcare Conference
Rare diseases drive high-teen growth and now represent 40% of 2025 revenue, with Isturisa’s U.S. label extension and Enjaymo’s integration fueling expansion. SPC remains stable, and disciplined R&D and BD support long-term targets despite FX and product headwinds.
Recordati price target lowered to EUR 48 from EUR 50 at Barclays
Barclays analyst Charles Pitman-King lowered the firm’s price target on Recordati (RCDTF) to EUR 48 from EUR 50 and keeps an Underweight rating on the shares.
Recordati price target raised to EUR 70 from EUR 67 at JPMorgan
JPMorgan raised the firm’s price target on Recordati (RCDTF) to EUR 70 from EUR 67 and keeps an Overweight rating on the shares.
Recordati Industria Chimica e Farmaceutica Transcript: Jefferies London Healthcare Conference 2025
Strong revenue and EBITDA growth were reported, with rare disease driving high teens growth and Isturisa’s peak sales guidance raised above €1.2 billion. Strategic investments and M&A continue, with 2026 marked as an investment year impacting margins, but long-term guidance and operational efficiency remain robust.
Recordati Industria Chimica e Farmaceutica Earnings Call Transcript: Q3 2025
Revenue grew 12.2% to €1.96B with strong rare disease momentum and U.S. growth over 30%. Isturisa’s peak sales estimate doubled to €1.2B+, driving major investment for expanded patient reach. FX headwinds and Cardicor license loss will impact 2026, but long-term growth outlook remains robust.
Recordati upgraded to Buy from Hold at Jefferies
Jefferies upgraded Recordati (RCDTF) to Buy from Hold with a price target of EUR 61.50, up from EUR 55. The firm cites the company’s improving margin visibility and sales momentum…
Italy's Recordati CEO sees rare disease drugs exempt from U.S. tariffs
The head of Italian group Recordati expects treatments for rare diseases to be exempted from the 15% tariff the United States plans to impose on imported European pharmaceutical products, he said on W...
Recordati Industria Chimica e Farmaceutica Earnings Call Transcript: Q2 2025
Revenue grew 11.7% year-over-year to EUR 1.32 billion, with strong gains in rare diseases and specialty care. EBITDA margin was 37.5%, and full-year guidance was confirmed despite FX headwinds. Vascepa and Vistariza are expected to drive future growth.
Five years after COVID, pharma shares languish in US policy limbo
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...
Recordati price target raised to EUR 56 from EUR 55.50 at RBC Capital
RBC Capital analyst Alistair Campbell raised the firm’s price target on Recordati (RCDTF) to EUR 56 from EUR 55.50 and keeps a Sector Perform rating on the shares. Published first…
Amarin announces exclusive license, supply agreement with Recordati
Amarin (AMRN) announced that the Company has entered into an exclusive long-term license and supply agreement with Recordati (RCDTF) to commercialize VAZKEPA across 59 countries, focused in Europe. Th...
Recordati price target raised to EUR 67 from EUR 65 at JPMorgan
JPMorgan raised the firm’s price target on Recordati (RCDTF) to EUR 67 from EUR 65 and keeps an Overweight rating on the shares.
Recordati price target raised to EUR 55.50 from EUR 55 at RBC Capital
RBC Capital analyst Alistair Campbell raised the firm’s price target on Recordati (RCDTF) to EUR 55.50 from EUR 55 and keeps a Sector Perform rating on the shares. Published first…
Recordati Industria Chimica e Farmaceutica Earnings Call Transcript: Q1 2025
Q1 2025 saw 11.9% revenue growth to €680M, with strong gains in both specialty/primary care and rare disease. EBITDA margin was 39.7%, and adjusted net income rose 7.2%. Full-year guidance and 2027 double-digit growth targets were reaffirmed.
RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%
Milan, 8 th May 2025 – The Board of Directors of Recordati S.p.A. approved the Group's Interim Report as of 31st March 2025, representing additional voluntary financial reporting(7). The Report was pr...
Recordati Industria Chimica e Farmaceutica Transcript: Investor Update
Ambitious targets include doubling revenue by 2030 and achieving €3–3.2 billion revenue by 2027, driven by diversified growth in specialty care and rare diseases. Recent product approvals and disciplined M&A support strong financial performance and resilience.
Recordati upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank upgraded Recordati (RCDTF) to Hold from Sell with an unchanged price target of EUR 52. The firm now considers the stock’s risk/reward as more evenly balanced. Published first…
Recordati upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst Niall Alexander upgraded Recordati (RCDTF) to Hold from Sell with a EUR 52 price target
Recordati price target raised to EUR 55 from EUR 53 at RBC Capital
RBC Capital analyst Alistair Campbell raised the firm’s price target on Recordati (RCDTF) to EUR 55 from EUR 53 and keeps a Sector Perform rating on the shares. Published first…
Recordati Industria Chimica e Farmaceutica Earnings Call Transcript: Q4 2024
2024 saw double-digit revenue and profit growth, with rare diseases and specialty care both outperforming. 2025 guidance targets further margin expansion and strong top-line growth, supported by new product launches and increased peak sales targets for key assets.
Recordati downgraded to Sell from Hold at Deutsche Bank
Deutsche Bank analyst Niall Alexander downgraded Recordati (RCDTF) to Sell from Hold with an unchanged price target of EUR 52. The stock’s current valuation is “heavily skewed north of the…